-
AACR 2022: 100% CR rate in 3 months!
Time of Update: 2022-05-18
CORE1: Phase 2, single arm study of CG0070 combined with pembrolizumab in patients with non-muscle invasive bladder cancer (NMIBC) unresponsive to Bacillus Calmette-Guerin (BCG).
colorectal cancer breast cancer▌ References:▌ References:CORE1: Phase 2, single arm study of CG0070 combined with pembrolizumab in patients with non-muscle invasive bladder cancer (NMIBC) unresponsive to Bacillus Calmette-Guerin (BCG).
-
The UK MHRA has issued a positive opinion on the early treatment of lutetium (177Lu) vipivotide tetraxetan in prostate cancer
Time of Update: 2022-05-18
7 months in the lutetium (177Lu) vipivotide tetraxetan plus SOC group compared with 3.
3 months in the lutetium(177Lu) vipivotide tetraxetan plus SOC group versus 11.
3 months in the lutetium(177Lu) vipivotide tetraxetan plus SOC group versus 11.
-
This technology is expected to fundamentally treat cancer
Time of Update: 2022-05-18
In 2020, CRISPR gene editing technology won the Nobel Prize in Chemistry; on June 27, 2021, the first clinical data on the safety and efficacy of CRISPR gene editing in vivo was published at NEJM, and the results showed that a single intravenous injection of CRISPR can precisely edit targets in vivo cells, to treat genetic diseases .
-
Lancet Oncol: Efficacy and safety of three first-line treatment regimens for metastatic clear cell renal cell carcinoma
Time of Update: 2022-05-18
The most common treatment-related grade 3-4 adverse events were hepatic failure and lipase elevation (3%) in the nivolumab group and lipase elevation and lipase elevation in the nivolumab-ipilimumab group Dysfunction (6%), and hypertension (15%) was most common in the VEGFR-TKI group .
-
AACR 2022: BioNTech's CAR-T cell therapy for solid tumors has proven efficacy
Time of Update: 2022-05-18
FDA Leukemia LymphomaAmong 14 patients with relapsed or refractory advanced, CLDN6 + solid tumors, evaluable for efficacy 6 weeks after infusion of CAR-T cell therapy, 4 patients with testicular cancer and 2 patients with ovarian cancer experienced partial responses (PR), The overall response rate was nearly 43 % .
-
Can't figure out the abbreviation of chemotherapy regimen?
Time of Update: 2022-05-17
1. Lung cancerlung cancerFor non-small cell lung cancer ( NSCLC ) patients without driver mutations, chemotherapy remains the cornerstone of antitumor therapy .
Platinum-based two-drug chemotherapy is the most commonly used chemotherapy for non-small cell lung cancer .
-
AACR's blockbuster INSIGHT study: Combination therapy of tepotinib and gefitinib significantly improves progression-free survival and overall survival in patients with EGFR mutation-positive NSCLC with MET amplification
Time of Update: 2022-05-17
8 months), tepotinib (a potent, highly selective, once-daily [QD] MET inhibitor) plus gefitinib EGFR-mutant NSCLC and patients who have developed resistance to anti-EGFR therapy due to MET amplification have improved efficacy over chemotherapy (CTX) .
-
AACR 2022: TMB not a good biomarker for immune checkpoint inhibitors (RATIONALE 304 study)?
Time of Update: 2022-05-17
Research designFigure 1 RATIONALE 304 study designThe interim analysis showed that in patients with advanced non-squamous NSCLC, the combination of tislelizumab significantly improved PFS compared with chemotherapy alone (IRC assessment: P=0.
-
European Radiology: When multiple primary lung cancers are diagnosed, what do different imaging signs indicate?
Time of Update: 2022-05-17
Recently, a study published in the European Radiology journal explored the relationship between the imaging classification, gene mutation status and surgical prognosis of sMPLC, providing a valuable reference for further treatment and evaluation of this type of patients .
-
The State Food and Drug Administration issued a document to standardize the research and development of oncology drugs to reduce disorderly competition with the same target.
Time of Update: 2022-05-08
"The release of the guiding principles will play an important role in the standardized and innovative research and development of dual monoclonal antibody clinical drugs in China .
-
Companion diagnostics join hands with innovative drugs to open an era of precise tumor treatment
Time of Update: 2022-05-08
Recently, Aide Bio announced that it has reached a global companion diagnostic cooperation with AstraZeneca, an innovative tumor pharmaceutical company, and the cooperation market has expanded from China to global markets such as Japan and the European Union .
-
Roche and Teva reach innovative strategic cooperation to expand blood and tumor pipeline
Time of Update: 2022-05-08
Bian Xin, President of Roche Pharma ChinaCunda® is the original research and development of bendamustine hydrochloride independently developed by Teva, which was approved in China in 2018 for the treatment of patients with disease progression during/after treatment with rituximab or rituximab-containing regimens.
-
Preliminary analysis of safety and efficacy of ELCC 2022 sequential chemoradiotherapy followed by durvalumab in stage III NSCLC
Time of Update: 2022-04-27
The prognosis for stage III unresectable NSCLC is always generally poor, and in 2017, the PACIFIC study improved this situation, and curative concurrent chemoradiotherapy (cCRT) followed by durvalumab consolidation therapy significantly improved patient survival .
-
Advanced Materials Xi'an Jiaotong University Chen Xin/Zhang Yanmin develop smart spherical nucleic acids for synergistic tumor therapy
Time of Update: 2022-04-27
In this study, two types of spherical nucleic acids (SNAs) were prepared using gold nanoparticles (AuNPs), which are expected to provide various therapeutic approaches, These include oncogenic miRNAs inhibition (controlling the genetic environment), oncogenic miRNAs-triggered drug release, and oncogenic miRNAs-dependent photothermal convection (using the genetic environment) for effective, accurate, and sustained tumor therapy .
-
Discovery of new independent prognostic marker for triple-negative breast cancer Weekly Oncology
Time of Update: 2022-04-27
Clin Cancer Res: The ATTRACTION-3 study demonstrated that second-line nivolumab showed clinically meaningful improvements in long-term survival compared with chemotherapy in previously treated patients with advanced esophageal squamous cell carcinoma, and nivolumab was well tolerated Sex is good .
-
Hypoalbuminemia, pleural effusion... MET-TKI adverse event management method, do you know?
Time of Update: 2022-04-27
*Only for medical professionals to read and reference, learn quickly! Targeted therapy plays an important role in the comprehensive treatment of non-small cell lung cancer (NSCLC) . In recent years,
-
What is the efficacy of bendamustine combined with rituximab in the first-line treatment of extranodal marginal zone lymphoma?
Time of Update: 2022-04-27
pylori eradication In patients with gastric involvement after treatment failure, radiation therapy is the preferred approach .
Patients who received rituximab maintenance therapy after achieving CR or PR after BR showed longer PFS (5-year PFS rate of 94.
-
2022 EBMT cord blood transplantation for hematological malignancies with favorable engraftment rates and low TRM rates
Time of Update: 2022-04-27
Anthias et al conducted a related study to explore the safety and efficacy of different conditioning regimens combined with umbilical cord blood transplantation (UCBT) in the treatment of hematological malignancies .
-
US FDA approves world's first T-cell receptor (TCR) therapy Kimmtrak (tebentafusp)
Time of Update: 2022-04-27
In the final analysis of the trial, the study met its primary efficacy endpoint: tebentafusp monotherapy compared with investigator-selected regimens (82% Keytruda, 12% Yervoy, 6% dacarbazine) in clinical and Statistically significant survival advantage was demonstrated: significantly prolonged overall survival (OS) and reduced risk of death by 49% (HR = 0.
-
EGFR 20ins mutant lung cancer, Amivantamab is better than the existing treatment!
Time of Update: 2022-04-27
Amivantamab compared with real-world therapies in patients with advanced non- small cell lung cancer harboring EGFR exon 20 insertion mutations who progressed after platinum-based chemotherapy.